The Medical Letter on Drugs and Therapeutics
Panobinostat (Farydak) for Multiple Myeloma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved panobinostat (Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory drug. It is the first HDAC inhibitor to be approved for this indication.

MULTIPLE MYELOMA — Use of drug regimens that include the proteasome inhibitor bortezomib1 plus thalidomide (Thalomid) or lenalidomide (Revlimid),2 a thalidomide analog, has led to improved response rates and survival in patients with multiple myeloma. Carfilzomib (Kyprolis),3 a second proteasome inhibitor, is approved for treatment of refractory multiple myeloma. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Panobinostat (Farydak) for Multiple Myeloma (online only)
Article code: 1475e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian